Why the study?
The study was conducted to evaluate the impact of Type 2 diabetes mellitus duration on major adverse cardiovascular events following percutaneous coronary intervention.
Does longer duration of Type 2 diabetes mellitus increase the risk of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention?
Population
465 T2DM patients undergoing PCI
Comparison
DM duration < 5 years vs 5-10 years vs > 10 years
Design
Single-center prospective cohort study
Follow-up
1-year
Key result
T2DM duration >10 years was associated with a significantly higher risk of MACE after PCI compared to <5 years (13.9% vs 3.7%; HR 4.37; 95% CI 1.59-12.01; p=0.004).
Authors
Loading...
T2DM duration may inform post-PCI risk stratification; extends observational data but leaves open whether it should guide therapy or trial design.
Cohort (n=465)
No
Does longer duration of Type 2 diabetes mellitus increase the risk of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention?
Hazard Ratio: 4.37 (95% CI 1.59–12.01)
Absolute Event Rate: 13.9% vs 3.7%
p-value: p=0.004
Longer duration of Type 2 diabetes mellitus (especially >10 years) is strongly associated with an increased risk of major adverse cardiovascular events at 1 year following percutaneous coronary intervention.
Tariq et al. (2026) conducted a cohort in Type 2 diabetes mellitus undergoing percutaneous coronary intervention (n=465). Type 2 diabetes mellitus duration > 10 years vs. Type 2 diabetes mellitus duration < 5 years was evaluated on MACE, a composite of nonfatal myocardial infarction (MI), stroke, coronary artery bypass grafting (CABG), repeat PCI, and mortality (HR 4.37, 95% CI 1.59-12.01, p=0.004). T2DM duration >10 years was associated with a significantly higher risk of MACE after PCI compared to <5 years (13.9% vs 3.7%; HR 4.37; 95% CI 1.59-12.01; p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: